Chondrogenic Potential of Mesenchymal Stem Cells from Patients with Rheumatoid Arthritis and Osteoarthritis: Measurements in a Microculture System
Chondrogenic Potential of Mesenchymal Stem Cells from Patients with Rheumatoid Arthritis and Osteoarthritis: Measurements in a Microculture System
复制标题
DOI：
10.1159/000140679
复制
发表时间：
2009-01-01
影响因子：
2.7
通讯作者：
Uher, Ferenc
中科院分区：
文献类型：
--
作者：
Dudics, Valeria;Kunstar, Aliz;Uher, Ferenc
背景：间充质干细胞（MSC）具有分化成不同间充质组织的潜力；包括软骨和骨，它们可以成为软骨组织工程方法的有吸引力的细胞来源。我们的目的是比较从类风湿性关节炎 (RA) 和骨关节炎 (OA) 患者中分离的 MSC 与来自正常供体的细胞的体外软骨形成潜力。方法：在骨手术期间取出骨髓样本并建立贴壁细胞培养物。然后将细胞转移到新开发的微聚集体培养系统中，培养基中含有转化生长因子β3、胰岛素、地塞米松和/或脱矿骨基质。体外软骨形成活性通过沉淀培养物中代谢硫酸盐掺入和 II 型胶原表达来测量。结果：来自 RA 和 OA 患者的培养扩增 MSC 在体外软骨形成潜力方面与正常人群没有显着差异。在存在适当的生长和分化因子的情况下，所有细胞制剂的总蛋白和蛋白聚糖合成能力以及细胞聚集体的胶原蛋白 II mRNA 表达能力相似。硫酸软骨素和葡萄糖胺等软骨保护药物可以增强软骨形成，而氯喹则抑制正常供体来源或患者来源的 MSC 培养物中的软骨形成。 Galectin-1 是一种具有显着抗炎活性的 β-半乳糖苷结合蛋白，在低（
Background: Mesenchymal stem cells (MSCs) have the potential to differentiate into distinct mesenchymal tissues; including cartilage and bone, they can be an attractive cell source for cartilage tissue engineering approaches. Our objective here was to compare the in vitro chondrogenic potential of MSCs isolated from patients with rheumatoid arthritis (RA) and osteoarthritis (OA) with cells from normal donors. Methods: Marrow samples were removed during bone surgery and adherent cell cultures were established. The cells were then passed into a newly developed microaggregate culture system in a medium containing transforming growth factor beta 3, insulin, dexamethasone and/or demineralized bone matrix. In vitro chondrogenic activity was measured as metabolic sulfate incorporation and type II collagen expression in pellet cultures. Results: Culture-expanded MSCs from RA and OA patients did not differ significantly from the normal population with respect to their chondrogenic potential in vitro. Capability of total protein and proteoglycan synthesis as well as collagen II mRNA expression by cell aggregates was similar for all cell preparations in the presence of the appropriate growth and differentiation factors. Chondroprotective drugs such as chondroitin sulfate and glucosamine enhanced, whereas chloroquine inhibited chondrogenesis in normal donor-derived or patient-derived MSC cultures. Galectin-1, a beta-galactoside-binding protein with marked anti-inflammatory activity, stimulated the chondrogenic differentiation of mesenchymal cells in low (